Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Research Foundation Launches Honorary Board of Advisors

  |  

Nearly 150 of the Rheumatology Research Foundation’s most generous supporters gathered in November during the 2015 ACR/ARHP Annual Meeting for the Donors of Merit recognition event. In celebration of the Foundation’s 30th Anniversary in 2015, the event reflected on the journey to advance treatments and improve patient care. The Foundation’s president, David Karp, MD, PhD,…

The ACR Advances Rheumatology Through Simple Tasks Campaign

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  

It’s a scenario that occurs all too often. After you tell someone you’re a rheumatologist, you receive that look—the blank stare, as if you’ve spoken to them in a foreign language. Six years ago, this scenario sparked a conversation among the ACR’s leaders about the importance of promoting our profession to the public, including key…

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Gene Manipulation Has Potential to Alter Genomes, Impact Society

  |  

Every so often, a major scientific breakthrough profoundly alters the trajectory of scientific research. In the 1960s, microbiologists sparked the recombinant-DNA revolution with the discovery that bacteria have innate immune systems based on restriction enzymes. These enzymes bind and cut invading viral genomes at specific short sequences, and scientists rapidly repurposed them to cut and…

Set Realistic Career Goals to Reach Your Professional Potential

Set Realistic Career Goals to Reach Your Professional Potential

  |  

As a rheumatologist, you’re used to having goals. After all, you set your sights on becoming a physician, achieved the necessary educational degrees and passed required exams. After meeting your educational goals, you landed a job at an academic medical center or an established rheumatology practice, or you may have started your own practice. So…

French ‘Cannabis’ Drug Trial Leaves 1 Brain Dead, 5 Injured

Matthias Blamont  |  

PARIS (Reuters)—One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in western France of an experimental medicine from an unnamed drug company, the French health ministry said on Friday, Jan. 15. The ministry did not say what the medicine was intended to be used…

Drug Shortages in U.S. Emergency Departments on the Rise

Madeline Kennedy  |  

(Reuters Health)—U.S. emergency rooms are increasingly running short on medications, including many that are needed for life-threatening conditions, a recent study documents. Since 2008, the number of shortages has risen by more than 400%, researchers found. Half of all emergency room shortages were for life-saving drugs, and for one in 10 there were no available…

U.S. Patent Office Rules Against Amgen Humira Challenge

Bill Berkrot  |  

(Reuters)—U.S. patent officials on Thursday denied petitions by Amgen to review two formulation patents on AbbVie’s Humira (adalimumab), a potential setback in Amgen efforts to market a biosimilar version of the world’s top-selling prescription medicine. In June, Amgen, the world’s biggest biotechnology company, asked the U.S. Patent and Trademark Office for the review, arguing that…

Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA

Reuters Staff  |  

NEW YORK (Reuters Health)—Almost half of juvenile idiopathic arthritis (JIA) patients treated with etanercept achieve minimal disease activity after one year of treatment, according to new findings. Younger patients and those who did not require corticosteroid treatment were more likely to have an excellent response, Dr. Kimme Hyrich of the University of Manchester in the…